FAS and breast carcinoma: Our research group reported that in the hormone-dependent breast cancer cell line CG5, AdoMet synergized with doxorubicin in inhibiting proliferation via Fas/FasL signaling pathway activation [31] and that in the breast cancer cell line MCF-7, the combined treatment of AdoMet and chloroquine, an autophagic inhibitor, showed a synergistic induction of both growth inhibition and apoptosis, by inhibiting the AKT/mTOR signaling pathway [30].